Biosimilar Biologics Do Not Always Reduce Out-of-Pocket Costs

TUESDAY, April 2, 2024-- Biosimilar competition is not consistently associated with lower out-of-pocket (OOP) costs for commercially insured outpatients, according to a study published online March 29 in JAMA Health Forum.Kimberly Feng, M.D.,...